Literature DB >> 23235484

Usual and unusual neuroendocrine tumor metastases on (68)Ga-DOTANOC PET/CT: a pictorial review.

Niraj Naswa1, Punit Sharma, Rakesh Kumar, Arun Malhotra, Chandrasekhar Bal.   

Abstract

Neuroendocrine tumors (NETs) are slow-growing indolent tumors that often present with metastatic disease at the outset. They commonly metastasize to lymph nodes, liver, bone, and lungs. However, metastasis to other rare sites may occur. It is important to have clear knowledge of unusual NET metastatic sites because their presence may lead to a more directed investigation. Also, it will be helpful in ruling out incidental second malignancies that might be encountered. The objective of this pictorial article was to provide an illustrative tutorial showing the clinical utility of Ga-labeled somatostatin analog [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI3-octreotide (Ga-DOTANOC) PET/CT for imaging usual and unusual metastatic sites in patients with NETs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23235484     DOI: 10.1097/RLU.0b013e318252d2c3

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report.

Authors:  Yasunaru Sakuma; Yoshikazu Yasuda; Naohiro Sata; Yoshinori Hosoya; Atsushi Shimizu; Hirofumi Fujii; Daisuke Matsubara; Noriyuki Fukushima; Atsushi Miki; Misato Maeno; Alan Kawarai Lefor
Journal:  BMC Cancer       Date:  2017-01-09       Impact factor: 4.430

2.  Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma.

Authors:  Emily B Ambinder; Rudolf A Werner; Steven P Rowe
Journal:  Radiol Case Rep       Date:  2020-06-25

3.  Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).

Authors:  Mina M Swiha; Duncan E K Sutherland; Golmehr Sistani; Alireza Khatami; Rami M Abazid; Amol Mujoomdar; Daniele P Wiseman; Jonathan G Romsa; Robert H Reid; David T Laidley
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-10       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.